Spruce Biosciences (NASDAQ: SPRB) raises about $69.0 million in equity sale
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Spruce Biosciences entered into an underwriting agreement for a public sale of 1,150,000 shares of common stock at $50.00 per share and pre-funded warrants to purchase 50,000 shares at $49.99 each. Underwriters also exercised a 30-day option to buy 180,000 additional shares at the public price.
The transaction is expected to generate approximately $69.0 million in gross proceeds before fees, providing new capital to the company. The pre-funded warrants carry a $0.01 exercise price and limits that generally cap any holder’s beneficial ownership at 4.99%, with the ability to elect up to 9.99% with advance notice.
Positive
- None.
Negative
- None.
Insights
Spruce secures about $69.0M in new equity capital via an underwritten offering.
Spruce Biosciences completed an underwritten public sale of common stock and pre-funded warrants, including full exercise of the underwriters’ option for 180,000 extra shares. The company expects gross proceeds of approximately $69.0 million before underwriting discounts and expenses.
This primary equity raise increases cash resources to fund late-stage neurological programs but also adds new shares and warrants. The pre-funded warrants have a $0.01 exercise price and include 4.99% and 9.99% beneficial ownership caps, which can influence how concentrated individual holdings become.
8-K Event Classification
3 items: 1.01, 8.01, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Common shares offered: 1,150,000 shares
Pre-funded warrants offered: 50,000 warrants
Public offering price per share: $50.00 per share
+5 more
8 metrics
Common shares offered
1,150,000 shares
Underwritten public offering of common stock
Pre-funded warrants offered
50,000 warrants
Pre-funded warrants to purchase common stock
Public offering price per share
$50.00 per share
Price to the public for common stock
Pre-funded warrant price
$49.99 per warrant
Public price per pre-funded warrant
Warrant exercise price
$0.01 per share
Exercise price of each pre-funded warrant
Additional shares option
180,000 shares
Underwriters’ 30-day option, exercised in full
Expected gross proceeds
approximately $69.0 million
Total before underwriting discounts and expenses
Beneficial ownership cap
4.99%–9.99%
Pre-funded warrant holder ownership limitation
Key Terms
Pre-Funded Warrants, underwritten public offering, shelf registration statement on Form S-3, beneficially own, +1 more
5 terms
Pre-Funded Warrants financial
"and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 50,000 shares of Common Stock"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
underwritten public offering financial
"announced that it has commenced an underwritten public offering of shares of its common stock"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
shelf registration statement on Form S-3 regulatory
"pursuant to a shelf registration statement on Form S-3, including a base prospectus"
A shelf registration statement on Form S-3 is a pre-approved filing with the Securities and Exchange Commission that lets an eligible public company register securities in advance and sell them later in one or more offerings without repeating the full registration process. Think of it like a pre-approved funding line: it gives management the flexibility to raise capital quickly when market conditions are right, a move that can affect share supply, dilution and investor returns, so investors monitor it as a signal of potential financing activity.
beneficially own financial
"would beneficially own more than 4.99% of the number of shares of Common Stock outstanding"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Offering Details
shelf
Offering
Offering Type
shelf
FAQ
What did Spruce Biosciences (SPRB) announce in its latest equity transaction?
Spruce Biosciences entered an underwritten public offering for common stock and pre-funded warrants, including an option for extra shares. The deal raises approximately $69.0 million in gross proceeds before fees, strengthening the company’s cash position for its late-stage neurological disorder programs.
How large is Spruce Biosciences’ new offering of SPRB common stock and warrants?
The offering includes 1,150,000 shares of common stock at $50.00 each and pre-funded warrants for 50,000 shares at $49.99 each. Underwriters also exercised an option for 180,000 additional shares, bringing expected gross proceeds to approximately $69.0 million before fees.
What are the key terms of Spruce Biosciences’ pre-funded warrants?
The pre-funded warrants allow purchase of 50,000 common shares with a $0.01 exercise price per share. They are exercisable any time after issuance, but each holder is generally limited to 4.99% beneficial ownership, adjustable up to 9.99% with at least 61 days’ prior written notice.
When is Spruce Biosciences’ public offering expected to close?
The company expects the underwritten public offering of common stock and pre-funded warrants to close on April 22, 2026. Closing remains subject to customary conditions detailed in the underwriting agreement between Spruce Biosciences and the underwriting syndicate led by major investment banks.
Under which registration statement is the Spruce Biosciences offering being made?
The shares of common stock and pre-funded warrants are being offered under an effective shelf registration statement on Form S-3. That registration statement includes a base prospectus and is supplemented by a prospectus supplement describing specific offering terms and related risk disclosures.